{"id":1998,"date":"2026-01-27T18:14:45","date_gmt":"2026-01-27T17:14:45","guid":{"rendered":"https:\/\/studienportal-eierstockkrebs.de\/n-plus\/"},"modified":"2026-02-13T12:22:26","modified_gmt":"2026-02-13T11:22:26","slug":"n-plus","status":"publish","type":"post","link":"https:\/\/studienportal-eierstockkrebs.de\/tr\/n-plus\/","title":{"rendered":"N-PLUS"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

NOGGO ov53\/ ENGOT-ov62 - N-Plus<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

T\u00fcm\u00f6rs\u00fcz cerrahi ge\u00e7irmi\u015f hastalarda kemoterapi d\u00f6ng\u00fclerinin say\u0131s\u0131n\u0131 ve dolay\u0131s\u0131yla kemoterapi s\u00fcresini azaltmay\u0131 ama\u00e7layan d\u00fcnyan\u0131n ilk \u00e7al\u0131\u015fmas\u0131. N-Plus, ilerlemi\u015f yumurtal\u0131k kanseri i\u00e7in ba\u015flang\u0131\u00e7 tedavisi g\u00f6ren HRD-pozitif hastalara y\u00f6nelik bir \u00e7al\u0131\u015fmad\u0131r. <\/strong><\/h2>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

N-PLUS, birinci basamak tedavide ilerlemi\u015f, y\u00fcksek dereceli HRD pozitif yumurtal\u0131k kanseri olan t\u00fcm\u00f6rs\u00fcz hastalarda 3 ve 6 k\u00fcr platin bazl\u0131 kemoterapiden sonra niraparibin<\/em> non-inferioritesine ili\u015fkin randomize (tedavi kollar\u0131na rastgele tahsis), k\u00f6r olmayan (t\u00fcm taraflar kimin ne ald\u0131\u011f\u0131n\u0131 bilir) bir faz II \u00e7al\u0131\u015fmad\u0131r.<\/p>

Bu \u00e7al\u0131\u015fmada ne analiz ediliyor? <\/strong><\/p>

Bug\u00fcne kadar kad\u0131nlara kanser te\u015fhisi konulduktan sonra 6 k\u00fcr kemoterapi uygulanmas\u0131 standart bir uygulama olmu\u015ftur. Kemoterapi genellikle ciddi olabilen ve hatta hastalar\u0131n tedaviyi b\u0131rakmas\u0131na yol a\u00e7abilen yan etkilerle ili\u015fkilidir. Ge\u00e7mi\u015f \u00e7al\u0131\u015fmalardan elde edilen kan\u0131tlar, daha az kemoterapi d\u00f6ng\u00fcs\u00fcn\u00fcn ard\u0131ndan niraparib gibi bir PARP inhibit\u00f6r\u00fc ile tedavinin daha fazla d\u00f6ng\u00fc ile tedaviden daha az etkili olmad\u0131\u011f\u0131n\u0131 g\u00f6stermektedir – ancak daha az yan etkiye sahip olma \u015fans\u0131 muhtemelen daha y\u00fcksektir. <\/p>

\u00c7al\u0131\u015fman\u0131n amac\u0131 nedir? <\/strong><\/p>

Bu \u00e7al\u0131\u015fman\u0131n amac\u0131, makroskopik t\u00fcm\u00f6rs\u00fcz cerrahi ge\u00e7irmi\u015f y\u00fcksek dereceli yumurtal\u0131k kanserli hastalarda \u00fc\u00e7 k\u00fcr kemoterapi(karboplatin\/paklitaksel<\/em>) ve ard\u0131ndan niraparib<\/em> ile idame tedavisinin etkinlik ve g\u00fcvenli\u011finin, 6 k\u00fcr kemoterapi ve ard\u0131ndan niraparib<\/em> ile idame tedavisinin etkisinden daha d\u00fc\u015f\u00fck olmad\u0131\u011f\u0131n\u0131 g\u00f6stermektir. Bu nedenle soru, 3 k\u00fcr ile 6 k\u00fcr ile ayn\u0131 tedavi ba\u015far\u0131s\u0131n\u0131n elde edilip edilemeyece\u011fi ve yan etkilerin kemoterapi ile azalt\u0131l\u0131p azalt\u0131lamayaca\u011f\u0131d\u0131r. <\/p>

\u00c7al\u0131\u015fma nas\u0131l organize edildi? <\/strong><\/p>

Hastalar rastgele (1:1) iki tedavi kolundan birine tahsis edilir, 3 k\u00fcr veya 6 k\u00fcr kemoterapi alma olas\u0131l\u0131\u011f\u0131 ayn\u0131d\u0131r (50:50). Hastalar bu \u00e7al\u0131\u015fman\u0131n bir par\u00e7as\u0131 olarak 15 dakikal\u0131k iki anket doldurur ve ayr\u0131ca ek kan testleri ve \u00e7al\u0131\u015fma ziyaretleri yap\u0131l\u0131r. Kemoterapiden sonra niraparib<\/em> kanser k\u00f6t\u00fcle\u015fene kadar veya en fazla 3 y\u0131l boyunca uygulan\u0131r. Tabletler g\u00fcnl\u00fck olarak al\u0131n\u0131r. <\/p>

Herhangi bir risk var m\u0131? <\/strong><\/p>

Bir bilgilendirme oturumu s\u0131ras\u0131nda kat\u0131l\u0131mla ili\u015fkili olas\u0131 riskler ve yan etkiler hakk\u0131nda bilgilendirileceksiniz.<\/p>

Kat\u0131l\u0131m gereksinimleri<\/strong><\/p>

Bu \u00e7al\u0131\u015fmaya 18 ya\u015f ve \u00fczeri kad\u0131nlar kat\u0131labilir:<\/p>

– HRD-pozitif, y\u00fcksek dereceli, ilerlemi\u015f over, fallop t\u00fcp\u00fc veya primer peritoneal karsinom
– Evre III veya IV
– Tam cerrahi tedavi<\/p>

Bununla birlikte, \u00e7al\u0131\u015fmaya kat\u0131lmak i\u00e7in kar\u015f\u0131lanmas\u0131 gereken ba\u015fka kriterler de vard\u0131r. \u0130lgilenen hastalar, bu \u00e7al\u0131\u015fman\u0131n kendileri i\u00e7in uygun olup olmad\u0131\u011f\u0131n\u0131 kontrol edebilecek bir \u00e7al\u0131\u015fma merkezindeki ara\u015ft\u0131rmac\u0131larla konu\u015fmal\u0131d\u0131r. <\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t

\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u00c7al\u0131\u015fmaya nerede kat\u0131labilirim?<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/path><\/svg>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tAlmanya haritas\u0131na<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

NOGGO ov53\/ ENGOT-ov62 – N-Plus T\u00fcm\u00f6rs\u00fcz cerrahi ge\u00e7irmi\u015f hastalarda kemoterapi d\u00f6ng\u00fclerinin say\u0131s\u0131n\u0131 ve dolay\u0131s\u0131yla kemoterapi s\u00fcresini azaltmay\u0131 ama\u00e7layan d\u00fcnyan\u0131n ilk \u00e7al\u0131\u015fmas\u0131. N-Plus, ilerlemi\u015f yumurtal\u0131k kanseri i\u00e7in ba\u015flang\u0131\u00e7 tedavisi g\u00f6ren HRD-pozitif hastalara y\u00f6nelik bir \u00e7al\u0131\u015fmad\u0131r. N-PLUS, birinci basamak tedavide ilerlemi\u015f, y\u00fcksek dereceli HRD pozitif yumurtal\u0131k kanseri olan t\u00fcm\u00f6rs\u00fcz hastalarda 3 ve 6 k\u00fcr platin bazl\u0131 kemoterapiden […]<\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[47,45],"tags":[],"class_list":["post-1998","post","type-post","status-publish","format-standard","hentry","category-calismalar","category-birincil-durum"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/comments?post=1998"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1998\/revisions"}],"predecessor-version":[{"id":2001,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/posts\/1998\/revisions\/2001"}],"wp:attachment":[{"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/media?parent=1998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/categories?post=1998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-eierstockkrebs.de\/tr\/wp-json\/wp\/v2\/tags?post=1998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}